The cancer genomics resource list 2014

Mary M. Zutter, Kenneth J. Bloom, Liang Cheng, Ian S. Hagemann, Jill H. Kaufman, Alyssa M. Krasinskas, Alexander J. Lazar, Debra G B Leonard, Neal I. Lindeman, Ann M. Moyer, Marina N. Nikiforova, Jan A. Nowak, John D. Pfeifer, Antonia R. Sepulveda, Joseph E. Willis, Sophia L. Yohe

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Context.-Genomic sequencing for cancer is offered by commercial for-profit laboratories, independent laboratory networks, and laboratories in academic medical centers and integrated health networks. The variability among the tests has created a complex, confusing environment. Objective.-To address the complexity, the Personalized Health Care (PHC) Committee of the College of American Pathologists proposed the development of a cancer genomics resource list (CGRL). The goal of this resource was to assist the laboratory pathology and clinical oncology communities. Design.-The PHC Committee established a working group in 2012 to address this goal. The group consisted of site-specific experts in cancer genetic sequencing. The group identified current next-generation sequencing (NGS)-based cancer tests and compiled them into a usable resource. The genes were annotated by the working group. The annotation process drew on published knowledge, including public databases and the medical literature. Results.-The compiled list includes NGS panels offered by 19 laboratories or vendors, accompanied by annotations. The list has 611 different genes for which NGS-based mutation testing is offered. Surprisingly, of these 611 genes, 0 genes were listed in every panel, 43 genes were listed in 4 panels, and 54 genes were listed in 3 panels. In addition, tests for 393 genes were offered by only 1 or 2 institutions. Table 1 provides an example of gene mutations offered for breast cancer genomic testing with the annotation as it appears in the CGRL 2014. Conclusions.-The final product, referred to as the Cancer Genomics Resource List 2014, is available as supplemental digital content.

Original languageEnglish
Pages (from-to)989-1008
Number of pages20
JournalArchives of Pathology and Laboratory Medicine
Volume139
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Genomics
Genes
Neoplasms
Delivery of Health Care
Mutation
Medical Oncology
Databases
Pathology
Breast Neoplasms
Health

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Zutter, M. M., Bloom, K. J., Cheng, L., Hagemann, I. S., Kaufman, J. H., Krasinskas, A. M., ... Yohe, S. L. (2015). The cancer genomics resource list 2014. Archives of Pathology and Laboratory Medicine, 139(8), 989-1008. https://doi.org/10.5858/arpa.2014-0330-CP

The cancer genomics resource list 2014. / Zutter, Mary M.; Bloom, Kenneth J.; Cheng, Liang; Hagemann, Ian S.; Kaufman, Jill H.; Krasinskas, Alyssa M.; Lazar, Alexander J.; Leonard, Debra G B; Lindeman, Neal I.; Moyer, Ann M.; Nikiforova, Marina N.; Nowak, Jan A.; Pfeifer, John D.; Sepulveda, Antonia R.; Willis, Joseph E.; Yohe, Sophia L.

In: Archives of Pathology and Laboratory Medicine, Vol. 139, No. 8, 01.08.2015, p. 989-1008.

Research output: Contribution to journalArticle

Zutter, MM, Bloom, KJ, Cheng, L, Hagemann, IS, Kaufman, JH, Krasinskas, AM, Lazar, AJ, Leonard, DGB, Lindeman, NI, Moyer, AM, Nikiforova, MN, Nowak, JA, Pfeifer, JD, Sepulveda, AR, Willis, JE & Yohe, SL 2015, 'The cancer genomics resource list 2014', Archives of Pathology and Laboratory Medicine, vol. 139, no. 8, pp. 989-1008. https://doi.org/10.5858/arpa.2014-0330-CP
Zutter MM, Bloom KJ, Cheng L, Hagemann IS, Kaufman JH, Krasinskas AM et al. The cancer genomics resource list 2014. Archives of Pathology and Laboratory Medicine. 2015 Aug 1;139(8):989-1008. https://doi.org/10.5858/arpa.2014-0330-CP
Zutter, Mary M. ; Bloom, Kenneth J. ; Cheng, Liang ; Hagemann, Ian S. ; Kaufman, Jill H. ; Krasinskas, Alyssa M. ; Lazar, Alexander J. ; Leonard, Debra G B ; Lindeman, Neal I. ; Moyer, Ann M. ; Nikiforova, Marina N. ; Nowak, Jan A. ; Pfeifer, John D. ; Sepulveda, Antonia R. ; Willis, Joseph E. ; Yohe, Sophia L. / The cancer genomics resource list 2014. In: Archives of Pathology and Laboratory Medicine. 2015 ; Vol. 139, No. 8. pp. 989-1008.
@article{cce18e4464984221a9bdb2967900e31a,
title = "The cancer genomics resource list 2014",
abstract = "Context.-Genomic sequencing for cancer is offered by commercial for-profit laboratories, independent laboratory networks, and laboratories in academic medical centers and integrated health networks. The variability among the tests has created a complex, confusing environment. Objective.-To address the complexity, the Personalized Health Care (PHC) Committee of the College of American Pathologists proposed the development of a cancer genomics resource list (CGRL). The goal of this resource was to assist the laboratory pathology and clinical oncology communities. Design.-The PHC Committee established a working group in 2012 to address this goal. The group consisted of site-specific experts in cancer genetic sequencing. The group identified current next-generation sequencing (NGS)-based cancer tests and compiled them into a usable resource. The genes were annotated by the working group. The annotation process drew on published knowledge, including public databases and the medical literature. Results.-The compiled list includes NGS panels offered by 19 laboratories or vendors, accompanied by annotations. The list has 611 different genes for which NGS-based mutation testing is offered. Surprisingly, of these 611 genes, 0 genes were listed in every panel, 43 genes were listed in 4 panels, and 54 genes were listed in 3 panels. In addition, tests for 393 genes were offered by only 1 or 2 institutions. Table 1 provides an example of gene mutations offered for breast cancer genomic testing with the annotation as it appears in the CGRL 2014. Conclusions.-The final product, referred to as the Cancer Genomics Resource List 2014, is available as supplemental digital content.",
author = "Zutter, {Mary M.} and Bloom, {Kenneth J.} and Liang Cheng and Hagemann, {Ian S.} and Kaufman, {Jill H.} and Krasinskas, {Alyssa M.} and Lazar, {Alexander J.} and Leonard, {Debra G B} and Lindeman, {Neal I.} and Moyer, {Ann M.} and Nikiforova, {Marina N.} and Nowak, {Jan A.} and Pfeifer, {John D.} and Sepulveda, {Antonia R.} and Willis, {Joseph E.} and Yohe, {Sophia L.}",
year = "2015",
month = "8",
day = "1",
doi = "10.5858/arpa.2014-0330-CP",
language = "English",
volume = "139",
pages = "989--1008",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "8",

}

TY - JOUR

T1 - The cancer genomics resource list 2014

AU - Zutter, Mary M.

AU - Bloom, Kenneth J.

AU - Cheng, Liang

AU - Hagemann, Ian S.

AU - Kaufman, Jill H.

AU - Krasinskas, Alyssa M.

AU - Lazar, Alexander J.

AU - Leonard, Debra G B

AU - Lindeman, Neal I.

AU - Moyer, Ann M.

AU - Nikiforova, Marina N.

AU - Nowak, Jan A.

AU - Pfeifer, John D.

AU - Sepulveda, Antonia R.

AU - Willis, Joseph E.

AU - Yohe, Sophia L.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Context.-Genomic sequencing for cancer is offered by commercial for-profit laboratories, independent laboratory networks, and laboratories in academic medical centers and integrated health networks. The variability among the tests has created a complex, confusing environment. Objective.-To address the complexity, the Personalized Health Care (PHC) Committee of the College of American Pathologists proposed the development of a cancer genomics resource list (CGRL). The goal of this resource was to assist the laboratory pathology and clinical oncology communities. Design.-The PHC Committee established a working group in 2012 to address this goal. The group consisted of site-specific experts in cancer genetic sequencing. The group identified current next-generation sequencing (NGS)-based cancer tests and compiled them into a usable resource. The genes were annotated by the working group. The annotation process drew on published knowledge, including public databases and the medical literature. Results.-The compiled list includes NGS panels offered by 19 laboratories or vendors, accompanied by annotations. The list has 611 different genes for which NGS-based mutation testing is offered. Surprisingly, of these 611 genes, 0 genes were listed in every panel, 43 genes were listed in 4 panels, and 54 genes were listed in 3 panels. In addition, tests for 393 genes were offered by only 1 or 2 institutions. Table 1 provides an example of gene mutations offered for breast cancer genomic testing with the annotation as it appears in the CGRL 2014. Conclusions.-The final product, referred to as the Cancer Genomics Resource List 2014, is available as supplemental digital content.

AB - Context.-Genomic sequencing for cancer is offered by commercial for-profit laboratories, independent laboratory networks, and laboratories in academic medical centers and integrated health networks. The variability among the tests has created a complex, confusing environment. Objective.-To address the complexity, the Personalized Health Care (PHC) Committee of the College of American Pathologists proposed the development of a cancer genomics resource list (CGRL). The goal of this resource was to assist the laboratory pathology and clinical oncology communities. Design.-The PHC Committee established a working group in 2012 to address this goal. The group consisted of site-specific experts in cancer genetic sequencing. The group identified current next-generation sequencing (NGS)-based cancer tests and compiled them into a usable resource. The genes were annotated by the working group. The annotation process drew on published knowledge, including public databases and the medical literature. Results.-The compiled list includes NGS panels offered by 19 laboratories or vendors, accompanied by annotations. The list has 611 different genes for which NGS-based mutation testing is offered. Surprisingly, of these 611 genes, 0 genes were listed in every panel, 43 genes were listed in 4 panels, and 54 genes were listed in 3 panels. In addition, tests for 393 genes were offered by only 1 or 2 institutions. Table 1 provides an example of gene mutations offered for breast cancer genomic testing with the annotation as it appears in the CGRL 2014. Conclusions.-The final product, referred to as the Cancer Genomics Resource List 2014, is available as supplemental digital content.

UR - http://www.scopus.com/inward/record.url?scp=84938614359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938614359&partnerID=8YFLogxK

U2 - 10.5858/arpa.2014-0330-CP

DO - 10.5858/arpa.2014-0330-CP

M3 - Article

C2 - 25436904

AN - SCOPUS:84938614359

VL - 139

SP - 989

EP - 1008

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 8

ER -